The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Vikram Purohit - Morgan Stanley - Analyst
: Hi, good morning. Thanks for taking our questions. We had two both on immunology first. So you alluded to in your prepared remarks, potential
pipeline expansion for 474. To the extent possible, I was wondering if you could speak a bit about what's going to feed into that decision and how
the datasets we get in the first half of next year for HS and AD might be related to how you think about with Sanofi, where to go next with this
molecule.
And then a similar question for 621 and 294. What will you be assessing from the initial clinical data we're going to be getting next year to help
prioritize indications for subsequent development and IND indications? Thank you.
Question: Vikram Purohit - Morgan Stanley - Analyst
: Got it. Thank you.
Question: Adam Vogel - Wells Fargo - Analyst
: Thank you for taking my call today. I'm on for Derek. So maybe just a few quick questions from us on oncology pipeline. Can you walk us through
further, what data you expect to share from KT-253 will be reading out data from both Arms A and B. And then perhaps on given your deepening
focus and efforts in I&I, will you be looking to partner either at 333 or 253 in the future? Thank you.
Question: Adam Vogel - Wells Fargo - Analyst
: Great, thank you.
Question: Marc Frahm - TD Cowen - Analyst
: Thanks for taking my questions. Maybe Nello IRAK4 when we get the data next year and Sanofi will make their own decision of going forward or
not. But you guys will also have -- well Sanofi chooses to move forward. You guys will have an opt-in decision, say how are you kind of approaching
that the opt-in? What do you want to see that you would commit Kymera's resources early on and how important is kind of the Phase 1 data from
STAT6 and TYK2 and seeing kind of exposure you want to make that decision IRAK4?
Question: Marc Frahm - TD Cowen - Analyst
: Okay, thanks. Very helpful.
Question: Brad Canino - Stifel, Nicolaus & Company, Incorporated - Analyst
: Good morning. This is Brad. Perhaps an expansion of the prior questions really for MDM2 and the data this year would be great to get just more of
a scope of the disclosure that you expect to present in terms of patient's disease types. And would you flag any key data elements to watch. And
just maybe to be clear on the decision making process at this disclosure, will you be in a position to outline the broader development thesis? Thank
you.
Question: Kalpit R. Patel - B. Riley Securities, Inc. - Analyst
: Hey, good morning and thanks for taking the question. One for the STAT6 and TYK2 program, you've shown data from their proteome study to
confirm the selectivity and maybe rule out the off-target effects. Can you share how many proteins were identified in those studies and what the
coverage rate was in those proteome studies? Thank you.
Question: Kalpit R. Patel - B. Riley Securities, Inc. - Analyst
: Okay, thank you.
| 
